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1. Introduction
In the pharmaceutical industry, the process of drug develop-
ment is very expensive and time-consuming. Typically, the US
$1–1.5 billion and several years are estimated to be needed for
the development of a new drug before extensive clinical
examinations [1]. Such a cost and time only contribute to
about a quarter of the total costs and time needed for the
entrance of a new drug into the markets. Also, such an invest-
ment in early-stage drug discovery determines the quality of
the final compound and its success rate in clinical trial phases.
It is critical to control and manage the costs per an FDA-
approved drug so that the R&D output in the pharmaceutical
industry can be optimized. Molecular imaging (MI) techniques
are of great assistance to reduce the costs of drug discovery
processes [2]. To select a compound for clinical development,
its pharmacokinetic and pharmacodynamic properties must
be optimized so that the best candidate can be selected.
Pharmacokinetics and pharmacodynamics imply what the
body does to the drug and what the drug does to the body.
These two components are quite critical to be known in the
process of drug discovery. It is also essential to precisely
determine the actions of a new drug, from the molecular
target to the clinical effects. In the area of drug discovery,
in vivo MI techniques allow us to address two important and
crucial queries [1]: how much drug gets a specific site in the
body and [2] what does drug do? To answer these questions,
a huge amount of money and time must be consumed if the
conventional methods are applied. Recently, an enormous
growing body of MI techniques such as Magnetic Resonance
Imaging (MRI), Positron Emission Tomography (PET), Single
Photon Emission Computed Tomography (SPECT), Computed
Tomography (CT), and Optical Imaging modalities has been
examined to accelerate the drug discovery process and keep
the R&D costs under control. Due to a great deal of capabilities
from viewpoints of speed, cost, availability, and efficiency,
micro-CT based MI techniques need to receive greater atten-
tion. In this opinion, a critical perspective on the importance of
molecular micro-CT imaging methods and their impact on
early-stage drug discovery process is provided. On the other
hand, with the emergence of nanotechnology and its poten-
tials in production of all-in-one theranostic nanoparticles, the
impact of CT imaging technique or its related hybrid imaging
modalities (such as MR/CT or SPECT/CT) on drug discovery
process is being further highlighted [3–6]. We expect that
the integration of molecular micro-CT scan technique and all-
in-one theranostic nanoparticles can revolutionize the future
procedures of drug discovery. In the rest of the current editor-
ial, we separately provide a short introductory overview of
molecular micro-CT imaging and all-in-one theranostic nano-
particles. Finally, we discuss our visions in the opinion section.
2. Molecular micro-CT scan
Imaging techniques are of critical importance in disease man-
agement and play an essential role in the process of disease
diagnosis and staging, treatment planning, and evaluation of
therapeutic efficiency. Typical structural imaging modalities
such as CT, MRI, and ultrasound are able to provide anatomical
information and allow us to find the location of an abnorm-
ality inside the body. However, such imaging techniques are
not adequately efficient in identifying the lesions or abnorm-
alities that are smaller than 0.5 cm, and they can barely report
the function of a specific organ. Molecular imaging (MI) is an
emerging arena that combines the concepts of molecular
biology with in vivo imaging so that a great deal of informa-
tion regarding various biological processes can be obtained.
Presently, nuclear medicine (NM) modalities such as PET and
SPECT are the main MI modalities widely used in both clinical
and investigational fields. However, NM modalities offer only
functional information regarding biological processes, mole-
cules, and metabolites. Therefore, it is obvious that NM mod-
alities have poor ability to provide anatomical information.
Today, micro-CT is one of the most useful diagnostic tools
capable of providing anatomical information. Micro-CT scan is
a powerful technique capable of scanning a sample at various
degrees using an x-ray to form 2D projections of the sample.
Furthermore, a 3D volume can be generated using the collected
2D projections with the help of computer-based reconstruction
techniques [7]. Therefore, the final output of micro-CT imaging
technique is a high-resolution 3D volume. Interestingly, in this
technique, manipulation and slicing of the obtained 3D volume
in any orientation are easily feasible. 2D or 3D resolution implies
the detail a slice or a volume holds. Higher resolution reflects
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more details. Resolution is usually described in many various
ways such as pixel resolution and spatial resolution. More details
about these terms may be found in other references [8]. Figure 1
shows a typical manipulable 3D volume obtained from a rat
brain and the feasibility to characterize a brain lesion through
micro-CT imaging. Similar potential is available to study various
abnormalities in other organs such as liver, spleen, and kidneys. It
can be also stated that the micro-CT imaging technique is of
great assistance to study the structural effects of a new drug on
various organs, but it cannot provide any information regarding
functional effects.
On the other hand, micro-CT scan is not considered as an MI
modality since appropriate targeted and molecularly specific con-
trast agents have not yet been introduced into the clinics. Current
CT contrast agents aremainly based on iodine which is effective in
absorbing x-rays. Iodine-based CT contrast agents can be conju-
gated to various biomolecules, but it is very hard for such con-
jugates to be detected because of low sensitivity of conventional
CT scanners. Therefore, in addition to the micro-CT imaging tech-
nique development, there exists an essential need to develop
some new multifunctional complexes containing the new drug
which is under investigation, CT contrast agent, and targeting/
biomarker ligand [9–11]. By the emergence of nanotechnology,
development of such multifunctional complexes has been rapidly
grown. Such multifunctional complexes produced by nanotech-
nology-based procedures are usually named as theranostic nano-
particles. With fabricating and taking advantages of theranostic
nanoparticles and high-resolution 3D images provided by micro-
CT scan, a great deal of information regarding drug actions is
expected to be provided.
3. Theranostic nanoparticles and their impact on
molecular micro-CT scan
The idea of production of theranostic nanoparticles is origi-
nated from the integration of three various concepts, as
shown in Figure 2. Theranostic nanoparticles are generally
made for concurrent diagnostic and therapeutic uses. As
shown in Figure 2, an ideal theranostic nanoparticle includes
three main features [1]: it contains a targeting ligand and can
selectively and rapidly accumulate in diseased tissue [2]; it
usually has a central imaging core capable to report biochem-
ical and morphological characteristics of the target area [3]; it
can also deliver a therapeutic material to diseased tissue [12].
Nanoparticles made of high Z materials (such as gold, bis-
muth, barium, and tungsten) are the main components of ther-
anostic nanoparticles which can be used as the CT scan contrast
agents [13]. Such nanoparticles can be easily entrapped into
a nanocarrier to be accompanied by drugs or genes [9–11].
They can be also conjugated with various targeting agents [14].
With regard to the mentioned potentials of theranostic nanopar-
ticles and the capabilities of CT scan imaging, we can determine
the biodistribution profile of new drug formulations [13,15]. This
is also a good idea for longitudinal studies with the minimum
level of invasiveness and without the need to sacrifice the ani-
mals which are under examinations. To describe this scenario
better, two important examples are presented. The first example
is related to taking advantage of the potentials of both thera-
nostic nanoparticles and micro-CT scan. The second one is
related to only taking advantage of the capability of high-
resolution images provided by micro-CT scan.
Example 1. Suppose that the pharmacokinetic and pharma-
codynamic investigations for a new drug are of interest.
Routinely, we characterize the time-course and distribution
of a drug in the liver, spleen, kidneys, and blood after injection
to the animals in a period of time (for example; in a month).
This action gives us valuable information, but we need to
sacrifice huge numbers of animals, consume much time, and
pay much money for investigators and technicians. Compare
this situations with the below story:
At first, we design a theranostic nano-system made of gold
nanoparticles (as the CT contrast agent) and the new drug
molecules. Various designations can be made to produce
a theranostic nano-system which are out of the scope of this
Figure 1. Feasibility of brain lesion characterization in small animals (such as rat) through micro-CT imaging technique. (a) A typical manipulable 3D volume of a rat
brain. (b, c) Processed micro-CT images showing a lesion in the context of a rat brain from two viewpoints. Reprinted from open access Ref. [7]. Copyright 2018
Nature Publishing Group.
Figure 2. The origin of theranostic nanoparticles and their essential
components.
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editorial. However, after producing theranostic nano-system, it
can be injected to animals and various organs (such as liver
and spleen) can be scanned longitudinally in a period of time
(for example; every day or every week). In fact, we can easily
characterize the time-course and distribution of a new drug
inside the animal body using micro-CT imaging. In this
method, we don’t need to sacrifice the animals at various
stages of the study and they can be kept alive, after CT scan,
for further examinations.
Example 2. Suppose that the toxic effects of a new drug on
liver, spleen and kidneys are of interest to be precisely deter-
mined. Toxicity is usually developed gradually or immediately
following drug injection which can be detected by imaging
studies. The structural integrity in the liver, spleen and kidneys
can be easily evaluated using micro-CT imaging in a period of
time. Once endocytosed by the cells of mononuclear phago-
cytes, the mechanism of drug molecules distribution from circu-
lating blood leads to an accumulation in the Kupffer cells of the
liver and in the macrophages of the spleen. When we profile the
x-ray attenuation in the liver and spleen with micro-CT imaging,
we can assess the possible damages induced in these organs.
Such an assessment is simply feasible by comparing the pre-
injection images with post-injection ones. This is certainly of high
interest to be mentioned scientists have recently reported scan-
ning resolution of ~5μm for micro-CT imaging [7]. This is incred-
ibly good resolution to investigate the changes of surface area,
density and volume of the liver, spleen, kidneys, or even brain for
a long period of time post dosing. Also, micro-CT imaging seems
to be adequately efficient for liver and spleen evaluation in sub-
acute/chronic pharmacology and toxicology studies [16].
4. Conclusion
Micro-CT imaging can revolutionize the quality of current drug
discovery procedures, while it requires less labor and expertise.
Scientists continuously attempt to make micro-CT imaging more
useful for quantification and visualization of a new drug effects in
a rapid and non-invasive manner. With regard to the mentioned
potentials of theranostic nanoparticles and molecular micro-CT
scan, we can design a new scenario in the field of drug discovery.
It appears safe to conclude, based on what presented in this
editorial, the use of theranostic nanoparticles and micro-CT ima-
ging has a great potential to build a non-invasive imaging mod-
ality for various organs macro-morphology examinations.
Moreover, such a new rapid and non-invasive imaging modality
is of great assistance in longitudinal pharmacology and toxicology
studies up to 1 to 6 months [16].
5. Expert opinion
To study the action of a new drug, the conventional methods
in the field of drug discovery are traditional histological exam-
ination and blood sampling. For example, histological exam-
ination is conducted when we need to precisely determine if
a synthesized compound causes a lesion in important organs
such as brain or liver. Lesion detection and quantification
through histological examination of a sectioned organ is
a time-consuming process and greatly depends on manual
estimation. Particularly, sectioning is difficult and challenging
because it may lead to significant damage and distortion of
tissue. Therefore, the requirement for sectioning in histological
investigations makes the process slow and imprecise.
Accordingly, it can be stated there exists an essential need
to develop other techniques for quantification and visualiza-
tion of a new drug effects. Micro-CT imaging can be consid-
ered as one of the best alternative solutions for this challenge
because it is non-invasive, precise, accurate, rapid, less labor-
intensive, and it can provide more detailed results than con-
ventional methods. Furthermore, the micro-CT imaging can
provide 3D reconstructions of an organ with various section
thicknesses dependent on what we need to know (from 5 to
15 microns). The reconstructed images can be also segmented
manually or automatically. These are some examples of the
opportunities provided by micro-CT scan while the traditional
methods of drug discovery are disabled to provide such
a great deal of information.
Regardless of the well-known drawbacks of CT imaging
(e.g. low sensitivity to conventional iodine-based contrast
media or exposure to ionizing radiation), the key challenge
against further development of micro-CT imaging is that most
organ tissues are generally transparent to x-rays. Fortunately,
a variety of drug and radiopaque containing nanocarriers exist
that can adequately overcome soft tissues contrast problems
in a wide range of drug discovery studies [9,17–21]. Another
alternative method for 3D imaging and drug effects visualiza-
tion is microscopic magnetic resonance imaging [7]. Although
micro-MRI, compared to micro-CT, has greater soft tissue con-
trast sensitivity, the resolution of micro-MRI is poorer (~25μm).
Also, the micro-MRI technique is much more expensive
because the micro-MRI machine is much more costly to be
obtained and maintained [7]. Therefore, micro-CT scan has its
own priority to be utilized in new drug discovery procedures.
Considering the potentials of theranostic nanoparticles,
another possible application of micro-CT scan in drug discovery
is to precisely determine the pharmacological indices of a new
synthesized compound. We can also target a drug towards an
organ and study the drug effects, specifically. What stated here
shows that we advocate for synergies between the recent
advancements in micro-CT imaging and theranostic nanoparti-
cles so that some new drug discovery procedures can be devel-
oped. However, one of the major obstacles that we see is the
disconnection between recent advancements reported in the
field of micro-CT scan, nanotechnology, theranostics, and target-
ing approaches (Figure 3(a)). This is while the conventional drug
discovery procedures are still used extensively, and they can be
revolutionized if the concepts of molecular CT-scan, and modern
nano-systems are effectively combined. Such a wise combina-
tion can make a rapid movement for the gear of drug discovery
procedures in the near future (Figure 3(b)).
We believe that drug discovery procedures will be modified
and experienced even more progress by effective integration
of the molecular micro-CT scan and theranostic nanoparticles
benefits. Such a combination definitely has a great potential
to accelerate drug discovery procedures and reduce the costs
needed for the development of a new drug before extensive
clinical examinations. While the interest in micro-CT imaging
methods is experiencing an explosion, we also see a high
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chance for quick improvement of micro-CT based MI methods.
We expect further qualitative changes in drug discovery pro-
cedures if micro-CT imaging based MI methods are located at
their real site. Further, into the future, we expect that the CT
imaging based MI methods will be of great assistance to
develop image-guided drug delivery methods which they
can provide more quantitative estimations.
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